Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta-lactamases.
A strain of Escherichia coli containing TEM-1 and CTX-M-1 was tested in an in vitro pharmacokinetic model against ceftazidime with and without AM-112, a serine beta-lactamase inhibitor. Ceftazidime alone was less effective than ceftazidime plus AM-112, and a single dose was more effective than three fractionated doses.
Bowker
Karen E
KE
Bristol Centre for Antimicrobial Research & Evaluation, North Bristol NHS Trust, Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol, BS10 5NB United Kingdom. karen.bowker@north-bristol.swest.nhs.uk
Noel
Alan R
AR
Walsh
Timothy R
TR
Rogers
Chris A
CA
MacGowan
Alasdair P
AP
D002442:Ceftazidime / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D015169:Colony Count, Microbial; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology; D006207:Half-Life; D007769:Lactams / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000378:metabolism*
C476288:(1'R,5R,6R)-3-(4-amino-1,1-dimethyl-butyl)-6-(1'-hydroxyethyl)oxapenem-3-carboxylate; D004791:Enzyme Inhibitors; D007769:Lactams; D065093:beta-Lactamase Inhibitors; D002442:Ceftazidime; C055184:beta-lactamase TEM-3; D001618:beta-Lactamases; C034413:beta-lactamase TEM-1